ImmunoGen watched its shares fall by 50% when partner Roche revealed disappointing results for the pair's targeted cancer drug, casting doubts on the biotech's technology for creating armed antibodies.
ImmunoGen garnered considerable attention for the tech support role it played on Roche's armed antibody Kadcyla. But an attempt to steer one of its own antibody-drug conjugates through clinical studies ended in disaster today.
Antibody-drug conjugate superstar ImmunoGen has signed another agreement to lend its targeted drug technology to Novartis for an undisclosed cancer therapy.
ImmunoGen says it's struck a $200 million deal to collaborate with Eli Lilly ($LLY) on developing new armed antibodies.
Roche's Genentech picked up FDA approval for its late-stage breast cancer therapy Kadcyla, formerly T-DM1, which uses antibodies to deliver cancer drugs directly to the offending cells.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
Roche has gained the inside track in the final lap of a long and expensive race to win an FDA approval for the armed antibody T-DM1, a new approach to treating HER2-positive breast cancer that marks a significant advance for patients.
Roche and ImmunoGen's trastuzumab emtansine (T-DM1) slashed the risk of death by almost a third compared with standard treatment in the EMILIA Phase III trial in women with advanced breast cancer.
Investigators behind the big T-DM1 breast cancer program took the lid off the last big data box from its pivotal study this morning, revealing that the armed antibody delivered a 32% reduction in the risk of death among patients in the pivotal Phase III study when compared to the standard-of-care arm.
ImmunoGen's ($IMGN) antibody-drug conjugate (ADC) trastuzumab emtansine (T-DM1) has significantly improved survival in a Phase III trial in women with advanced breast cancer, and the agent has been submitted for marketing approval.